Skip to main content

24-01-2018 | Non-small-cell lung cancer | Article

The biology and management of non-small cell lung cancer


Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and multimodal care. The use of small molecule tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients. However, the overall cure and survival rates for NSCLC remain low, particularly in metastatic disease. Therefore, continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.

Herbst RS et a. Nature 2018; 553: 446–454. doi:10.1038/nature25183


Please log in to get access to this content

Related topics